No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

NGMedical GmbH Receives FDA Clearance for Its AM Titanium Lumbar Interbody BEE® PLIF

Editor: What To Know

  • Continuing with the design and development concepts of BEE Cervical, the BEE PLIF implant provides the surgeon maximum control in ultimate placement and surface area connectivity to achieve the best possible clinical outcome,”.
  • NGMedical, a German medical device manufacturer exclusively focused on creating innovative technologies for spinal application, announces FDA clearance for its purely additively manufactured titanium lumbar BEE® PLIF cage, which will be featured at NASS.
  • BEE PLIF is offered in a wide range of sizes up to 18° lordosis.

NGMedical, a German medical device manufacturer exclusively focused on creating innovative technologies for spinal application, announces FDA clearance for its purely additively manufactured titanium lumbar BEE® PLIF cage, which will be featured at NASS.

The BEE® PLIF cage has been created to benefit from additive manufacturing features. The purposefully designed honeycomb endplate design reduces the risk of subsidence, while allowing fusion. The honeycomb structure allows for bony ingrowth while offering a very large graft space. Smooth lateral surfaces facilitate insert and rotate technique. BEE PLIF is offered in a wide range of sizes up to 18° lordosis. This is another significant innovation from the team, who invented the first line of additively manufactured interbody devices.

“BEE PLIF is our next important development based on AM technology for the U.S. market. The design concept, known from our cervical BEE® cage, which was launched earlier this year, was the basis for this unique lumbar interbody device,” says Nino Weiland, Operations Manager of NGMedical.

“We are very excited to be able to introduce our first posterior implant to our innovative product portfolio. Continuing with the design and development concepts of BEE Cervical, the BEE PLIF implant provides the surgeon maximum control in ultimate placement and surface area connectivity to achieve the best possible clinical outcome,” according to Josh Sandberg of NGMedical, Inc.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy